Bendamustine plus rituximab shows promise in relapsed, refractory DLBCL Healio The combination of bendamustine and rituximab was effective and well tolerated as salvage therapy in patients with relapsed or refractory diffuse large B-cell lymphoma who underwent prior treatment with a rituximab-based therapy, according to results ... |
